Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

renal function
endocrine therapy
progesterone
platelet count
palbociclib 125 mg
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

local therapy
palbociclib
cancer
platelet count
metastasis
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib

  • 0 views
  • 27 Jan, 2021
  • 1 location
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

her2-negative breast cancer
HER2
progesterone
abemaciclib
measurable disease
  • 0 views
  • 18 Apr, 2021
  • 49 locations
Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by

endocrine therapy
platelet count
core needle biopsy
metastasis
hormone therapy
  • 4 views
  • 28 Jan, 2021
  • 63 locations
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with

HER2
palbociclib
her2/neu-negative breast cancer
letrozole
metastasis
  • 0 views
  • 17 Apr, 2021
  • 124 locations
Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine

endocrine therapy
metastatic cancer
pertuzumab
hormone therapy
liver metastasis
  • 544 views
  • 27 Jan, 2021
  • 132 locations
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2

endocrine therapy
HER2
palbociclib
primary tumor
breast-conserving surgery
  • 0 views
  • 24 Jan, 2021
  • 1 location
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

. Palbociclib (Ibrance) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in this study. Palbociclib is used to treat patients with hormone receptor

endocrine therapy
aromatase inhibitor
gnrh
exemestane
HER2
  • 0 views
  • 18 Apr, 2021
  • 67 locations
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable Hormone Sensitive and HER2-Negative Primary Breast Cancer

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy

endocrine therapy
HER2
her-2
cancer
invasive breast cancer
  • 43 views
  • 16 Apr, 2021
  • 27 locations